DANYELZA® (naxitamab-gqgk) 40mg/10mL Injection Administration and Management of Adverse Reactions
This module will delve into the process of DANYELZA® administration and management of adverse reactions. You will learn key aspects of preparing the patient to receive the infusion, premedication orders, and important strategies for handling pain and any adverse reactions.
Please see Important Safety Information including Boxed Warning on serious infusion-related reactions and neurotoxicity.
DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutic, Inc.